News
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
The experimental drug, NTLA-2001, is being developed for the treatment of transthyretin (ATTR) amyloidosis.
Saama Technologies secured a $430 million investment from the Carlyle Group and venture funds from some of the pharmaceutical industry’s biggest companies.
The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies.
Everyone wants a positive work environment but how do you find one? This article will provide you with deep insights into how you can find a company that you dream of.
Depression is the first indication, but other neurological conditions are being planned.
Shares of vTv Therapeutics fell in morning trading after the company announced the retirement of Stephen L. Holcombe, who has served as president and chief executive officer. Deepa Prasad is joining the company from a venture capital firm to take over the reins.
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
The National Academy of Medicine tapped 100 new members to its prestigious organization that represents some of the brightest minds in health and medicines. Here are some of them.
Biogen’s Aduhelm (aducanumab) reported only $300,000 in third-quarter sales compared to original analyst average estimates of $10.79 million.
The CDC has warned that COVID-19 during pregnancy can result in preterm birth and other negative outcomes, including stillbirths.